Top 10 Companies in the Global Synthetic Cannabinoid Market (2026): Market Leaders Powering Growth

MARKET INSIGHTS

Global synthetic cannabinoid market size was valued at USD 5.4 billion in 2025 and is projected to reach USD 15.2 billion by 2034, exhibiting a CAGR of 12.1% during the forecast period from 2026 to 2034.

Synthetic cannabinoids are artificially manufactured chemical compounds designed to interact with the body’s endocannabinoid system, primarily targeting the CB1 and CB2 receptors. These compounds mimic the effects of phytocannabinoids found in the cannabis plant but are engineered for greater consistency, specificity, and purity. The category encompasses a diverse range of molecular structures, including classical cannabinoids like THC analogs, non‑classical cannabinoids, aminoalkylindoles, and eicosanoids, each developed for specific pharmacological profiles.

The market is experiencing robust growth, primarily driven by the expanding pharmaceutical applications of these compounds for conditions such as chronic pain, chemotherapy‑induced nausea and vomiting, and spasticity associated with multiple sclerosis. Increasing research and development investments from major pharmaceutical and biotechnology companies, coupled with a gradual shift in regulatory landscapes favoring medical cannabis research, are key contributors to this expansion. Significant clinical trials investigating synthetic cannabinoids for neuropathic pain and epilepsy are bolstering market confidence. Key players operating in this market with substantial R&D portfolios include Noramco, Hyasynth Biologicals, and specialized biotech firms such as Ginkgo Bioworks.

Global Synthetic Cannabinoid Market – View in Detailed Research Report

TOP 10 COMPANIES

1️⃣ Noramco, Inc.

Headquarters: Irving, Texas, USA
Key Offering: Dronabinol API, controlled‑substance manufacturing services

Noramco’s legacy in regulated API production positions it as a go‑to supplier for pharmaceutical developers seeking ultra‑pure synthetic cannabinoids. The company’s compliance with DEA Schedule I and II licensing, combined with robust GMP infrastructure, enables rapid translation of research candidates into clinical candidates. By integrating advanced purification and real‑time analytics, Noramco consistently delivers compounds that meet the stringent safety and efficacy criteria required for drug approval.

Sustainability & Growth Initiatives:

• Investment in automated synthesis platforms to reduce batch variability
• Partnerships with contract development organizations to expand API volume
• Continuous improvement of waste‑management protocols to minimize environmental impact

2️⃣ Hyasynth Biologicals

Headquarters: Montreal, Canada
Key Offering: Yeast‑based biosynthesis of high‑purity synthetic cannabinoids

Hyasynth’s proprietary yeast platform delivers scalable production of ultra‑pure cannabinoids while reducing reliance on complex chemical synthesis. The platform’s modular design allows rapid iteration of analog libraries, supporting early‑stage discovery and preclinical development. By leveraging fermentation‑based processes, Hyasynth achieves lower production costs and a smaller carbon footprint, aligning with the growing demand for sustainable pharmaceutical manufacturing.

Sustainability & Growth Initiatives:

• Expansion of bioprocessing capacity to 10 M kg/year
• Collaboration with academic institutions on metabolic engineering
• Adoption of closed‑loop fermentation to recycle process streams

3️⃣ Ginkgo Bioworks

Headquarters: Boston, Massachusetts, USA
Key Offering: Engineered microbial hosts for cannabinoid biosynthesis

Ginkgo Bioworks combines synthetic biology with high‑throughput screening to produce a library of cannabinoid analogs. The company’s modular chassis platform enables rapid optimization of yield and purity, facilitating the development of next‑generation therapeutics. By integrating machine‑learning algorithms for strain design, Ginkgo accelerates the discovery of compounds with tailored receptor profiles.

Sustainability & Growth Initiatives:

• Partnerships with global pharma partners to co‑develop API pipelines
• Implementation of renewable energy sources in fermentation facilities
• Development of scalable downstream purification modules

4️⃣ Cayman Chemical Company

Headquarters: New York, New York, USA
Key Offering: Research‑grade synthetic cannabinoid reference standards

Cayman Chemical’s reputation for analytical rigor supports academic and industrial research. The company supplies certified reference materials with full spectral data, enabling precise compound identification and quality control. Its extensive catalog covers both classic and novel cannabinoid scaffolds, positioning it as a critical enabler for preclinical and clinical studies.

Sustainability & Growth Initiatives:

• Implementation of ISO 17025 accreditation for analytical testing
• Investment in digital traceability for reference material distribution
• Expansion of custom synthesis services for niche analogs

5️⃣ Siegfried AG

Headquarters: Basel, Switzerland
Key Offering: Contract development and manufacturing of high‑purity cannabinoid APIs

Siegfried’s long history in specialty chemicals and strong regulatory footprint enable it to navigate complex approval pathways. The company’s integrated platform—from synthesis to formulation—ensures consistency across batch releases, a critical factor for clinical development of cannabinoid therapeutics.

Sustainability & Growth Initiatives:

• Adoption of green chemistry principles in synthesis routes
• Expansion of European production facilities to meet growing demand
• Collaboration with academic partners on novel cannabinoid targets

6️⃣ Johnson Matthey – Pharmaceutical Materials & Services

Headquarters: London, United Kingdom
Key Offering: High‑purity cannabinoid APIs and formulation services

Johnson Matthey’s pharmaceutical division leverages its global GMP network to supply cannabinoids at scale. The company’s expertise in process development and regulatory strategy positions it as a trusted partner for drug developers seeking to advance compounds through clinical phases.

Sustainability & Growth Initiatives:

• Integration of renewable energy across manufacturing sites
• Investment in continuous flow synthesis to improve efficiency
• Strategic alliances with biotech startups to co‑develop early‑stage APIs

7️⃣ Librede (formerly Lygos)

Headquarters: San Diego, California, USA
Key Offering: Fermentation‑based cannabinoid production and custom synthesis

Librede’s flexible fermentation platform supports rapid scale‑up of novel cannabinoid analogs. The company’s focus on process optimization and quality assurance ensures that products meet the high standards required for clinical testing.

Sustainability & Growth Initiatives:

• Development of modular bioreactor systems for rapid deployment
• Collaboration with contract manufacturing organizations to expand capacity
• Implementation of closed‑loop water recycling in fermentation processes

8️⃣ Toronto Research Chemicals (TRC)

Headquarters: Toronto, Canada
Key Offering: High‑purity synthetic cannabinoid research compounds

TRC supplies a broad portfolio of research‑grade cannabinoids, supporting academic and industrial discovery programs. The company’s rigorous analytical validation and rapid turnaround times make it a preferred source for early‑stage research.

Sustainability & Growth Initiatives:

• Investment in high‑throughput synthesis for analog libraries
• Partnerships with universities for joint research initiatives
• Adoption of eco‑friendly solvents in synthesis routes

9️⃣ CV Sciences

Headquarters: San Diego, California, USA
Key Offering: Discovery‑grade synthetic cannabinoids and formulation services

CV Sciences focuses on early‑stage discovery of novel cannabinoid analogs. Its integrated platform—from design to preclinical formulation—accelerates the identification of therapeutic candidates with optimized pharmacokinetics and safety profiles.

Sustainability & Growth Initiatives:

• Development of continuous flow synthesis for scalable production
• Collaboration with academic institutions on receptor profiling
• Implementation of green chemistry practices across the value chain

🔟 Renew Biopharma

Headquarters: San Diego, California, USA
Key Offering: Clinical‑grade synthetic cannabinoid therapeutics

Renew Biopharma is advancing a portfolio of cannabinoid‑based drugs for pain and spasticity indications. The company’s focus on delivering high‑purity APIs and robust clinical development programs positions it as a key player in the therapeutic landscape.

Sustainability & Growth Initiatives:

• Partnerships with global pharma partners for clinical development
• Investment in advanced formulation technologies for oral delivery
• Implementation of lifecycle assessment to reduce environmental impact

Download FREE Sample Report: Global Synthetic Cannabinoid Market – View in Detailed Research Report

Get Full Report: Global Synthetic Cannabinoid Market – View in Detailed Research Report

OUTLOOK

Over the next decade, the synthetic cannabinoid market is poised to evolve beyond traditional therapeutic niches into broader neuro‑inflammatory and immunological indications. The convergence of biomanufacturing, advanced analytics, and streamlined regulatory pathways is expected to accelerate the entry of next‑generation CB2‑selective agents into clinical practice. Market participants who align their R&D portfolios with these emerging therapeutic windows, while maintaining rigorous safety and quality standards, will likely secure a competitive edge.

FUTURE TRENDS

• Selective CB2 agonists targeting neuropathic pain and inflammatory disorders
• Integration of machine‑learning‑driven design for rapid analog optimization
• Expansion of biomanufacturing facilities to meet global demand for ultra‑pure APIs
• Increased focus on sustainability metrics across the production lifecycle
• Growing role of reference standard suppliers in supporting forensic and regulatory testing